olsalazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| phenylazosalicylic acid derivatives antibacterial | 1988 | 6054-98-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
cpd with 2 salicylate molecules linked together by an azo bond
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 55.25 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 2 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.07 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.90 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 41 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 31, 1990 | FDA | MEDA PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Colitis ulcerative | 66.63 | 56.50 | 13 | 59 | 34729 | 79709587 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A07EC03 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFLAMMATORY AGENTS Aminosalicylic acid and similar agents |
| FDA CS | M0000971 | Aminosalicylic Acids |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| FDA EPC | N0000175781 | Aminosalicylate |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ulcerative colitis in remission | indication | 697969008 | |
| Crohn's disease | off-label use | 34000006 | |
| Ulcerative colitis | off-label use | 64766004 | DOID:8577 |
| Allergic rhinitis | contraindication | 61582004 | |
| Diarrhea | contraindication | 62315008 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.98 | acidic |
| pKa2 | 2.58 | acidic |
| pKa3 | 11.15 | acidic |
| pKa4 | 11.76 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Arachidonate 5-lipoxygenase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL | |||||
| Cyclooxygenase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Flavin reductase (NADPH) | Enzyme | Kd | 7.16 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019863 | VUID |
| N0000147949 | NUI |
| D00727 | KEGG_DRUG |
| 4019494 | VANDF |
| 4019572 | VANDF |
| 4019863 | VANDF |
| C0069454 | UMLSCUI |
| CHEBI:7770 | CHEBI |
| CHEBI:6775 | CHEBI |
| CHEMBL425 | ChEMBL_ID |
| DB01250 | DRUGBANK_ID |
| CHEMBL1201013 | ChEMBL_ID |
| C032587 | MESH_SUPPLEMENTAL_RECORD_UI |
| 22419 | PUBCHEM_CID |
| 11578 | IUPHAR_LIGAND_ID |
| 5607 | INN_ID |
| ULS5I8J03O | UNII |
| 104123 | RXNORM |
| 37855 | MMSL |
| 37856 | MMSL |
| 4448 | MMSL |
| 5056 | MMSL |
| 5200 | MMSL |
| d01031 | MMSL |
| d01032 | MMSL |
| 001600 | NDDF |
| 003554 | NDDF |
| 004656 | NDDF |
| 108673002 | SNOMEDCT_US |
| 108674008 | SNOMEDCT_US |
| 386890003 | SNOMEDCT_US |
| 387501005 | SNOMEDCT_US |
| 86977007 | SNOMEDCT_US |
| C0127615 | UMLSCUI |
| JBC | PDB_CHEM_ID |
| DB00244 | DRUGBANK_ID |
| 15722-48-2 | SECONDARY_CAS_RN |
| 4075 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Dipentum | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0037-6860 | CAPSULE, GELATIN COATED | 250 mg | ORAL | NDA | 25 sections |
| Dipentum | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0037-6860 | CAPSULE, GELATIN COATED | 250 mg | ORAL | NDA | 25 sections |
| Dipentum | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0037-6860 | CAPSULE, GELATIN COATED | 250 mg | ORAL | NDA | 25 sections |
| Dipentum | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0037-6860 | CAPSULE, GELATIN COATED | 250 mg | ORAL | NDA | 25 sections |
| Dipentum | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-0312 | CAPSULE, GELATIN COATED | 250 mg | ORAL | NDA | 25 sections |
| Dipentum | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-3120 | CAPSULE, GELATIN COATED | 250 mg | ORAL | NDA | 27 sections |